deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03018405

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)

Sponsor: Celyad Oncology SA

Conditions Acute Myeloid Leukemia/Myelodysplastic Syndrome Multiple Myeloma (MM)
Interventions NKR-2 cells
Updated 13 times since 2017 Last updated: Sep 18, 2019 Started: Dec 31, 2016 Primary completion: May 31, 2021 Completion: Aug 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia/Myelodysplastic Syndrome and Multiple Myeloma (MM) and is currently ongoing. Celyad Oncology SA leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Feb 2018 · 9 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Oct 2019 · 10 months · monthly snapshot~Oct 2019 – ~Jul 2020 · 9 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Oct 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  4. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Oct 2019 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  2. Dec 2018 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  6. May 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  7. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1

  8. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celyad Oncology SA
Data source: Celyad Oncology SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations